NO20002477L - Transgene modeller av inflammatoriske sykdommer - Google Patents

Transgene modeller av inflammatoriske sykdommer

Info

Publication number
NO20002477L
NO20002477L NO20002477A NO20002477A NO20002477L NO 20002477 L NO20002477 L NO 20002477L NO 20002477 A NO20002477 A NO 20002477A NO 20002477 A NO20002477 A NO 20002477A NO 20002477 L NO20002477 L NO 20002477L
Authority
NO
Norway
Prior art keywords
interleukin
knockout
inflammatory diseases
mammal
expression
Prior art date
Application number
NO20002477A
Other languages
English (en)
Other versions
NO20002477D0 (no
Inventor
Gordon W Duff
Martin Nicklin
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of NO20002477D0 publication Critical patent/NO20002477D0/no
Publication of NO20002477L publication Critical patent/NO20002477L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033Rearing or breeding invertebrates; New breeds of invertebrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • A01K2267/0325Animal model for autoimmune diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0368Animal model for inflammation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det beskrives et pattedyr hvor ekspresjonen av ett eller flere interleukin-gener er blitt undertrykt. Nærmere bestemt er det foretatt en inaktiverende delesjon av interleukin-1-reseptorantagonistgenet for å produsere et ikke-humant knockout- pattedyr med nedsatt eller fullstendig undertrykket ekspresjon av det endogene gen. Fremgangsmåter for fremstilling av slike knockout-pattedyr og for bruk av knockout- dyrene til evaluering av effekten av terapeutiske midler og regimer for behandling av sykdommer eller forstyrrelser assosiert med alvorlig forstyrrelse i interleukin-veiene, er også beskrevet.
NO20002477A 1997-11-13 2000-05-12 Transgene modeller av inflammatoriske sykdommer NO20002477L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723835.6A GB9723835D0 (en) 1997-11-13 1997-11-13 Interleukin knockout
PCT/US1998/024287 WO1999025857A2 (en) 1997-11-13 1998-11-13 Transgenic models of inflammatory disease

Publications (2)

Publication Number Publication Date
NO20002477D0 NO20002477D0 (no) 2000-05-12
NO20002477L true NO20002477L (no) 2000-07-12

Family

ID=10821919

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002477A NO20002477L (no) 1997-11-13 2000-05-12 Transgene modeller av inflammatoriske sykdommer

Country Status (13)

Country Link
EP (1) EP1030926A2 (no)
JP (1) JP2001523467A (no)
KR (1) KR20010015814A (no)
AU (1) AU1796699A (no)
BR (1) BR9814142A (no)
CA (1) CA2309807A1 (no)
GB (1) GB9723835D0 (no)
HU (1) HUP0004352A2 (no)
IL (1) IL136013A0 (no)
NO (1) NO20002477L (no)
PL (1) PL340829A1 (no)
TR (1) TR200001356T2 (no)
WO (1) WO1999025857A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
WO2001056606A1 (fr) * 2000-01-31 2001-08-09 Santen Pharmaceutical Co., Ltd. Remedes pour troubles ophtalmiques
KR20030067204A (ko) * 2002-02-07 2003-08-14 한국생명공학연구원 퍼록시레독신-ⅱ 유전자 결손 생쥐 및 이의 생산방법
EP1723235B1 (en) * 2004-02-12 2012-06-27 The Walter And Eliza Hall Institute Of Medical Research Modified cells that co-express blimp1 and a reporter molecule and methods of using the same
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Il−1タイプiiレセプター遺伝子の欠損変異体マウス
JP5186637B2 (ja) * 2009-07-30 2013-04-17 国立大学法人富山大学 トランスジェニック非ヒト哺乳動物およびその利用
WO2019235839A1 (ko) * 2018-06-05 2019-12-12 사회복지법인 삼성생명공익재단 그레이브스 안병증 표현형 동물 모델, 그의 제조방법 및 그레이브스 안병증 치료물질 스크리닝 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1269989B (it) * 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
EP0787179A4 (en) * 1994-10-20 1999-05-19 Merck & Co Inc TRANSGENIC ANIMALS WITH INTERLEUKIN-1-g (b) DEFICIENCY
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease

Also Published As

Publication number Publication date
BR9814142A (pt) 2000-10-03
TR200001356T2 (tr) 2000-08-21
AU1796699A (en) 1999-06-07
NO20002477D0 (no) 2000-05-12
HUP0004352A2 (en) 2001-03-28
KR20010015814A (ko) 2001-02-26
PL340829A1 (en) 2001-02-26
WO1999025857A3 (en) 1999-07-15
JP2001523467A (ja) 2001-11-27
CA2309807A1 (en) 1999-05-27
EP1030926A2 (en) 2000-08-30
WO1999025857A2 (en) 1999-05-27
IL136013A0 (en) 2001-05-20
GB9723835D0 (en) 1998-01-07

Similar Documents

Publication Publication Date Title
Shemer et al. Structure of the imprinted mouse Snrpn gene and establishment of its parental-specific methylation pattern
Guy et al. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome
Tait-Burkard et al. Livestock 2.0–genome editing for fitter, healthier, and more productive farmed animals
Zhou et al. Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer
Nordin et al. Epigenetic regulation of the Igf2/H19 gene cluster
Tueting et al. The phenotypic characteristics of heterozygous reeler mouse
Giesige et al. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD
Cheung et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X L to cause plasma cell neoplasms in mice
De Murcia et al. Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Chen et al. Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene
Giacometti et al. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2
O'Keefe et al. Chemical genetics define the roles of p38α and p38β in acute and chronic inflammation
ATE315085T1 (de) Transgene mäuse mit veränderter apolipoprotein e- expression und testverfahren.
DE69233477D1 (de) Transgene nicht-menschliche tiere ohne prionprotein
BR9811659A (pt) Clonagem de porcos usando-se núcleos doadores de células diferenciadas
ATE431849T1 (de) Zufuhr transposonbasierter vektoren zu fortpflanzungsorganen
Hernández-Santana et al. Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice
Suzuki et al. Generation and characterization of RAG2 knockout pigs as animal model for severe combined immunodeficiency
NO20002477L (no) Transgene modeller av inflammatoriske sykdommer
BR9811657A (pt) Clonagem usando-se núcleos doadores oriundos de células diferenciadas não-carentes de soro
Ding et al. Siglecg limits the size of B1a B cell lineage by down-regulating NFκB activation
Morishita et al. Deafness due to degeneration of cochlear neurons in caspase-3-deficient mice
Siegmund et al. Frontline: Interferon regulatory factor‐1 as a protective gene in intestinal inflammation: role of TCR γ δ T cells and interleukin‐18‐binding protein
IL146296A0 (en) Cell reprogramming
Kaklamanos et al. Experimental models of sjögren’s syndrome: Differences and similarities with human disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application